Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20,
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday.
The Dow traded down 0.40% to 34,850.49 while the NASDAQ fell 0.35% to 14,055.15. The S&P 500 also fell, dropping, 0.23% to 4,492.60.